Breast Cancer; Cutaneous Melanoma.

Programme Leader: Targeted Therapies for Cancer

Check out our recent MTCI Cancer Clinical Research Trust (CCRT) Translational Research in Oncology Symposium on Friday Sept. 30th & Saturday Oct. 1st 2016 here

DOWNLOAD PROGRAM

 

Research Groups

Cancer Research Group

Contact

Phone:+353 (01) 7007497
Fax:+353 (01) 700 5484
Email: norma.dononavan@dcu.ie
LinkedIn

Academic Background

B.Sc. UCC

Ph.D. UCC

Principal Research Interests

Molecularly targeted therapies for cancer

Kinases and signalling pathways in cancer

HER2 positive breast cancer

Triple negative breast cancer

Malignant melanoma

Selected Publications

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013 Oct;4(10):1592-605. PubMed PMID: 24009064.

Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat. 2012 Dec;136(3):717-27. doi: 10.1007/s10549-012-2260-9. PubMed PMID: 23117852.

Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. EGFR and HER2 inhibition in pancreatic cancer. Invest New Drugs. 2013 Jun;31(3):558-66. doi: 10.1007/s10637- 012-9891-x. PubMed PMID: 23076814.

Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2012 Jul;23(7):1788-95. doi: 10.1093/annonc/mdr484. PubMed PMID: 22056974.

Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011 Oct;22(10):2234-40. doi: 10.1093/annonc/mdq757. PubMed PMID: 21357651.

Share

EnglishJapanese